Looks like no magic bullets in the near future.
"The question now is how do we read across the G2/3 cirrhotic data to the G1 patient population — i.e. does (sofosbuvir GS-5885) work as well in cirrhotic G1 patients as non-cirrhotic G1 patients?" wrote ISI Group analyst Mark Schoenebaum in an email to clients. "We should know the answer to this by the end of 2013 as G1 phase 3 data emerge for that regimen."
http://news.investors.com/technology/021913-644899-gilead-hepatitis-c-drug-shines-in-trials.htm
A major unresolved issue is how the various drugs do in patients with cirrhosis, or excessive scarring, of the liver. In the most recent Gilead results, cirrhotic patients of both genotypes reported a 66% cure rate in the 16-week group — significantly fewer than the non-cirrhotic patients.
"The SVR rates for genotype 3 was 30 percent with 12 weeks of treatment and 62 percent after 16 weeks of therapy. That compared with SVR rates of 86 percent and 94 percent for genotype 2."
That's ugly for a G3 :(
Thanks for posting that link. Interesting article and findings.